Tags

Type your tag names separated by a space and hit enter

Obesity: Pharmacotherapy.
FP Essent. 2020 May; 492:25-29.FE

Abstract

Pharmacotherapy, adjunctively with lifestyle interventions, is an option for any patient diagnosed with obesity (ie, body mass index [BMI] of 30 kg/m2 or greater) or with a BMI of 27 kg/m2 or greater and at least one coexisting condition, including type 2 diabetes, hypertension, hyperlipidemia, and sleep apnea. If the appropriate criteria are met, pharmacotherapy should be initiated for patients with overweight or obesity if lifestyle modification does not produce adequate weight loss. Lifestyle modifications should be continued and emphasized throughout treatment because it has been shown that adjunctive pharmacotherapy produces greater weight loss and weight loss maintenance than lifestyle interventions alone. Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-naltrexone, and liraglutide. Certain drugs are approved for short-term management while others are approved for long-term management. Drug therapy should be customized to the individual patient, depending on needs, contraindications, and cost. Benefits of these drugs should be assessed regularly and a different drug should be considered if at least 5% of body weight is not lost by 3 months of therapy.

Authors+Show Affiliations

Lahey Medical Weight Loss, 50 Burlington Mall Road, Burlington, MA 01805.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32383845

Citation

Powell, Amanda. "Obesity: Pharmacotherapy." FP Essentials, vol. 492, 2020, pp. 25-29.
Powell A. Obesity: Pharmacotherapy. FP Essent. 2020;492:25-29.
Powell, A. (2020). Obesity: Pharmacotherapy. FP Essentials, 492, 25-29.
Powell A. Obesity: Pharmacotherapy. FP Essent. 2020;492:25-29. PubMed PMID: 32383845.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Obesity: Pharmacotherapy. A1 - Powell,Amanda, PY - 2020/5/9/entrez PY - 2020/5/10/pubmed PY - 2020/7/21/medline SP - 25 EP - 29 JF - FP essentials JO - FP Essent VL - 492 N2 - Pharmacotherapy, adjunctively with lifestyle interventions, is an option for any patient diagnosed with obesity (ie, body mass index [BMI] of 30 kg/m2 or greater) or with a BMI of 27 kg/m2 or greater and at least one coexisting condition, including type 2 diabetes, hypertension, hyperlipidemia, and sleep apnea. If the appropriate criteria are met, pharmacotherapy should be initiated for patients with overweight or obesity if lifestyle modification does not produce adequate weight loss. Lifestyle modifications should be continued and emphasized throughout treatment because it has been shown that adjunctive pharmacotherapy produces greater weight loss and weight loss maintenance than lifestyle interventions alone. Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-naltrexone, and liraglutide. Certain drugs are approved for short-term management while others are approved for long-term management. Drug therapy should be customized to the individual patient, depending on needs, contraindications, and cost. Benefits of these drugs should be assessed regularly and a different drug should be considered if at least 5% of body weight is not lost by 3 months of therapy. SN - 2159-3000 UR - https://www.unboundmedicine.com/medline/citation/32383845/Obesity:_Pharmacotherapy L2 - http://www.diseaseinfosearch.org/result/9028 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.